ROLE OF THE FETUS IN THE DEVELOPMENT OF PREECLAMPSIA


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Subjects and methods. Pregnant women at risk for preeclampsia who underwent cordocentesis at 22—24 weeks gestation for certain reasons, as well as their fetuses were prospectively examined. A study group comprised 82 patients who were divided into 2 subgroups: 1) pregnant women who were found to have abnormal uteroplacental and/or fetoplacental blood flow (AUPFPBF) at 22—28 weeks’ gestation (n=42); 2) those without signs of hemodynamic disorders in the maternal-placental-fetal system (n=40). Solid-phase enzyme immunoassay (ELISA) was used to examine sera from the pregnant women and their fetuses to determine antibodies against NSE and GFAP. Results. The probability of preeclampsia in pregnant women with AUPFPBF at 22—28 weeks’ gestation was 47.6% and the risk of this pregnancy complication was as great as 96.4% at 22—24 weeks if the levels of neuroantibodies signif icantly increased. The concentrations of neuroantibodies at 22—24 weeks’ gestation were signif icantly higher in the patients whose pregnancy was accompanied by symptoms of preeclampsia, particularly in the presence of AUPFPBF. The significant fetal serum concentrations of neuroantibodies were also detectable only if the mother developed preeclampsia. The maximum serum neuroantibody levels were found in both pregnant women and their fetuses in the cases of early clinical symptoms of preeclampsia, its severe forms attended by placental insufficiency, intrauterine growth retardation, AUPFPBF, placental detachment. Conclusion. The elevated concentrations of antibodies against neurospecific proteins in both the maternal and fetal sera are of high prognostic value for further progression of preeclampsia.

Full Text

Restricted Access

About the authors

I. S SIDOROVA

I.Μ. Sechenov First Moscow State Medical University

M. A KURTSER

Center for Family Planning and Reproduction, Moscow Healthcare Department

Email: cfp@list.ru

N. A NIKITINA

I.Μ. Sechenov First Moscow State Medical University

A. A RZAYEVA

I.Μ. Sechenov First Moscow State Medical University

References

  1. Бабич Г.Н., Белопасов В.В. Маркеры повреждения гематоэнцефалического барьера при нейроинфекциях // Нейроиммунология. — 2003. — Т. 1, № 1. — С. 51—56.
  2. Барашнев Ю.И. Перинатальная неврология. — М.: Триада-X, 2001.
  3. Блинов Д.В. Иммуноферментный анализ нейроспецифических антигенов в оценке проницаемости гематоэнцефалического барьера при перинатальном гипоксически-ишемическом поражении ЦНС (клинико-экспериментальное исследование): Автореф. дис.. канд. мед. наук. — М., 2004.
  4. Боголепова И.Н. Онтогенез мозга человека // Педиатрия. - 1997. - № 5. - С. 27-31.
  5. Боголепова И.Н. Основные закономерности формирования мозга ребенка в пренатальном онтогенезе // Южно-Рос. мед. журн. - 1999. - № 2. - С. 25-30.
  6. Внутриутробное развитие человека: Руководство для врачей / Под ред. А.П. Милованова, С.В. Савельева. -М.: МДВ, 2006.
  7. Гурина О.И. Клинико-иммунохимическая оценка нарушений функций гематоэнцефалического барьера у недоношенных детей с перинатальными поражениями центральной нервной системы: Автореф. дис. канд. мед. наук. - М., 1996.
  8. Иванова Л.А. Роль провоспалительных цитокинов в механизме дисфункции эндотелия сосудов плаценты при гестозе: Автореф. дис. канд. мед. наук. - СПб., 2003.
  9. Караганова Е.Я. Проницаемость гематоэнцефалического барьера у беременных, рожениц, плодов и новорожденных при ОПГ-гестозах: Автореф. дис.. канд. мед. наук. - М., 1996.
  10. Крыжановский Г.Н., Магаева С.В., Макаров С.В., Сепиашвили Р.И. Нейроиммунопатология: Руководство. - М.: НИИ общей патологии и патофизиологии, 2003.
  11. Петрищев Н.Н. Дисфункция эндотелия. Причины, механизмы, фармакологическая коррекция. - СПб.: Санкт-Петербург. гос. мед. ун-т им. И.П. Павлова, 2003.
  12. Свечников П.Д. Маркеры повреждения эндотелия при беременности, осложненной гестозом: Автореф. дис. канд. мед. наук. - СПб., 2000.
  13. Сидорова И.С. Гестоз. - М.: Медицина, 2003.
  14. Чехонин В.П., Дмитриева Т.Б., Жирков Ю.А. Иммунохимический анализ нейроспецифических антигенов. - М.: Медицина, 2000.
  15. Berger R., Garnier Y. Perinatal brain injury // J. Perinat. Med. - 2000. - Vol. 28, № 4. - P. 261-285.
  16. Borzychowski A.M., Sargent I.L., Redman C.W.G. Inflammation and pre-eclampsia // Semin. Fetal Neonatal Med. - 2006. - Vol. 11. - P. 309-316.
  17. Brunei H., Girard N., Confort-Gouny S. et al. Fetal brain injury // J. Neuroradiol. - 2004. - Vol. 31, № 2. - P. 123-137.
  18. Chaudhuri J.D. Blood brain barrier and infection // Med. Sci. Monit. - 2000. - Vol. 6, № 6. - P. 1213-1222.
  19. Chekhonin V.P., Lebedev S.V., Dmitrieva T.B. et al. Enzyme immunoassay of NSE and GFAP as the criterion of dynamic evaluation of the rat blood-brain barrier in perinatal hypoxic ischemic injury of the CNS // Bull.Exp. Biol. Med. -2003. - Vol. 136, № 3. - P. 261-265.
  20. Djurovic S., Clausen T., Wergeland R. et al. Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia // Br. J. Obstet. Gynaecol. - 2002. - Vol. 109, № 7. - P. 759-764.
  21. Heyl W., Heintz B., Reister F. et al. Increased soluble VCAM-1 serum levels in preeclampsia are not correlated to urinary excretion or circadian blood pressure rhythm // J. Perinat. Med. - 2005. - Vol. 33, № 2. - P. 144-148.
  22. Luppi P., Deloia J.A. Monocytes of preeclamptic women spontaneously synthesize pro-inflammatory cytokines // Clin. Immunol. - 2006. - Vol. 118, № 2-3. - P. 268-275.
  23. Madazli R., Benian A., Ilvan S., Calay Z. Placental apoptosis and adhesion molecules expression in the placenta and the maternal placental bed of pregnancies complicated by fetal growth restriction with and without pre-eclampsia // J. Obstet. Gynaecol. - 2006. - Vol. 26, № 1. - P. 5-10.
  24. Redman C.W., Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response: a review // Placenta. - 2003. - Vol. 24. - P. 21-27.
  25. Roberts J.M., Gammill H.S. Preeclampsia: recent insights // Hypertension. - 2005. - Vol. 4, № 6. - P. 1243-1249.
  26. Rusterholz C., Gupta A.K., Huppertz B. et al. Soluble factors released by placental villous tissue: Interleukin-1 is a potential mediator of endothelial dysfunction // Am. J. Obstet. Gynecol. - 2005. - Vol. 192, № 2. - P. 618-624.
  27. Shamshirsaz А.А., Paidas M., Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation // J. Pregnancy. -2012. - Vol. 2012. - 374047.
  28. Sibai B., Dekker G., Kupferminc M. Pre-eclampsia // Lancet. - 2005. - Vol. 365, № 9461. - P. 785-799.
  29. Uzan J., Carbonnel M., Piconne O. et al. Pre-eclampsia: pathophysiology, diagnosis, and management // Vasc. Hlth Risk Manag. - 2011. - Vol. 7. - P. 467-474.
  30. Wilson M.L., Goodwin T.M., Pan V.L., Ingles S.A. Molecular epidemiology of preeclampsia // Obstet. Gynecol. Surv. -2003. - Vol. 58, № 1. - P. 39-66.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies